<DOC>
	<DOC>NCT01149200</DOC>
	<brief_summary>Study is to assess the effectiveness of TC-6499 in the treatment of constipation predominant IBS patients over a 28-day period.</brief_summary>
	<brief_title>Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)</brief_title>
	<detailed_description>This is a randomized, double blind, placebo controlled study of a maximum of 24 subjects with constipation predominant irritable bowel syndrome (IBS-C). Sixteen subjects will receive active treatment and 8 subjects will receive matching placebo. There will be a 21-day screening phase before 1st study drug administration on Day 1.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Men with IBSC (ROME III) between 18 and 65 years of age, inclusive. Women with IBSC (ROME III) between 55 and 65 years of age, or 18 to 55 years of age with documentation of nonchildbearing potential status (surgical sterilization or one year post last menses with elevated FSH/LV). All subjects should have a body mass index (BMI) between 18 and 34 kg/m2, inclusive and a body weight of not less than 45 kg.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS-C</keyword>
</DOC>